Skip to main content

Advertisement

Log in

Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Naltrexone is an opioid antagonist that is currently approved as a treatment for opioid and alcohol dependence. Although it is highly effective in completely antagonizing the effects of opioids, medication noncompliance is a difficult obstacle to treatment. Therefore, a sustained-release form of naltrexone may improve treatment outcome.

Objective

The present study was designed to evaluate the time course, safety, and effectiveness of a depot formulation of naltrexone (Depotrex®).

Materials and methods

Five heroin-dependent individuals participated in an 8-week inpatient study. After a 1-week detoxification period, the effects of a range of heroin doses (0, 6.25, 12.5, and 25 mg, i.v.) were examined. Participants then received 384 mg naltrexone base. The effects of heroin were again evaluated for the next 6 weeks. One dose of heroin was tested per day and the entire dose range was tested each week. Doses were administered in non-systematic order. During a morning sample session, participants received a dose of heroin and $20 and subjective, performance, and physiological effects were measured both before and after drug administration. During an afternoon choice session, participants were given the opportunity to choose the sampled heroin dose and/or amount of money using a modified progressive ratio procedure.

Results

Depot naltrexone antagonized both the reinforcing and subjective effects of heroin for 4–5 weeks. Subjective ratings of withdrawal were reduced after week 2 and throughout the remainder of the study. The effects of heroin on mean trough pupil diameter began to emerge by week 5. There were no clinically significant effects on respiratory or cardiovascular function.

Conclusions

The present results extend our previous findings by showing that the reinforcing effects of heroin were reduced for 4–5 weeks after administration of 384 mg depot naltrexone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Alim TN, Tai B, Chiang CN, Green T, Rosse RB, Lindquist T, Deutsch SI (1995) Tolerability study of a depot form of naltrexone substance abusers. In: Harris LS (ed) Problems of drug dependence 1994, vol 2. NIDA Research Monograph No. 153 (NIH Publ. No. 95-3883). U.S. Government Printing Office, Washington, D.C., p 253

    Google Scholar 

  • Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Liberman RP (1980) The treatment of heroin addiction: naltrexone alone and with behavior therapy. Int J Addict 15(6):795-807

    PubMed  CAS  Google Scholar 

  • Chiang CN, Hollister LE, Gillespie HK, Foltz RL (1985a) Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend 16:1–8

    Article  PubMed  CAS  Google Scholar 

  • Chiang CN, Kishimoto A, Barnett G, Hollister LE (1985b) Implantable narcotic antagonists: a possible new treatment for narcotic addiction. Psychopharmacol Bull 21:672–675

    PubMed  CAS  Google Scholar 

  • Comer SD, Collins ED (2002) Self-administration of intravenous buprenorphine and buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 303(2):695–703

    Article  PubMed  CAS  Google Scholar 

  • Comer SD, Collins ED, Fischman MW (1997) Choice between money and intranasal heroin in morphine-maintained humans. Behav Pharmacol 8:667–690

    Article  Google Scholar 

  • Comer SD, Collins ED, Wilson ST, Donovan MR, Foltin RW, Fischman MW (1998) Effect of an alternative reinforcer on i.v. heroin self-administration by humans. Eur J Pharmacol 345:13–26

    Article  PubMed  CAS  Google Scholar 

  • Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW (2002) Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159:351–360

    Article  PubMed  CAS  Google Scholar 

  • Comer SD, Walker EA, Collins ED (2005) Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181(4):664–675

    Article  PubMed  CAS  Google Scholar 

  • Crowley TJ, Wagner JE, Zerbe G, Macdonald M (1985) Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 142:1081–1084

    PubMed  CAS  Google Scholar 

  • Evans SM, Foltin RW, Levin FR, Fischman MW (1995) Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 6:176–186

    PubMed  CAS  Google Scholar 

  • Foltin RW, Fischman MW (1992) The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J Pharmacol Exp Ther 261:623–632

    PubMed  CAS  Google Scholar 

  • Foltin RW, Fischman MW (1995) Interaction of buprenorphine with cocaine–morphine combinations. Exp Clin Psychopharmacol 3(3):261–269

    Article  CAS  Google Scholar 

  • Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs, (B) A short-term “direct” addiction test. J Pharmacol Exp Ther 133:371–387

    PubMed  CAS  Google Scholar 

  • Gossop M, Green L, Phillips G, Bradley B (1989) Lapse, relapse, and survival among opiate addicts after treatment: a prospective follow-up study. Br J Psychiatry 154:348–353

    PubMed  CAS  Google Scholar 

  • Greenstein RA, Arndt IC, McLellan AT, O’Brien CP, Evans B (1984) Naltrexone: a clinical perspective. J Clin Psychiatry 45:25–28

    PubMed  CAS  Google Scholar 

  • Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13:293–308

    PubMed  CAS  Google Scholar 

  • Heishman SJ, Francis-Wood A, Keenan RM, Chiang CN, Terrill JB, Tai B, Henningfield JE (1994) Safety and pharmacokinetics of a new formulation of naltrexone. In: Harris LS (ed) Problems of drug dependence 1993, vol 2. NIDA Research Monograph No. 141 (NIH Publ. No. 94-3749). U.S. Government Printing Office, Washington, D.C., p 82

    Google Scholar 

  • Heishman SJ, Schuh KJ, Schuster CR, Henningfield JE, Goldberg SR (2000) Reinforcing and subjective effects of morphine in human opioid abusers: effect of dose and alternative reinforcer. Psychopharmacology 148:272–280

    Article  PubMed  CAS  Google Scholar 

  • Hollister LE, Johnson K, Boukhabza D, Gillespie HK (1981) Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8:37–41

    Article  PubMed  CAS  Google Scholar 

  • Hollister LE, Schwin RL, Kapser P (1977) Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend 2:203–209

    Article  PubMed  CAS  Google Scholar 

  • Judson BA, Carney TM, Goldstein A (1981) Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend 7:325–346

    Article  PubMed  CAS  Google Scholar 

  • Kelly TH, Foltin RW, Emurian CS, Fischman MW (1993) Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 17:264–272

    PubMed  CAS  Google Scholar 

  • Kirchmayer U, Davoli M, Verster A, Amato L, Feri M, Perucci CA (2002) A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97(10):1241–1249

    Article  PubMed  Google Scholar 

  • Kosten TR, Kleber HD (1984) Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse 10:249–266

    PubMed  CAS  Google Scholar 

  • Kranzler HR, Modesto-Lowe V, Nuwayser ES (1998) Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 22:1074–1079

    Article  PubMed  CAS  Google Scholar 

  • Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, Goldberg SR (1991) The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259:1165–1173

    PubMed  CAS  Google Scholar 

  • Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28:784–791

    PubMed  CAS  Google Scholar 

  • Martin W, Sandquist VL (1974) A sustained release depot for narcotic antagonists. Arch Gen Psychiatry 30:31–33

    PubMed  CAS  Google Scholar 

  • McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the Digit Symbol Substitution Test (DSST). Behav Res Meth Instrum 14:463–466

    Google Scholar 

  • Mirin SM, Meyer RE, McNamee HB (1976) Psychopathology, craving, and mood during heroin acquisition: an experimental study. Int J Addict 11:525–544

    PubMed  CAS  Google Scholar 

  • Oncken C, Kirk JV, Kranzler HR (2001) Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154:397–402

    Article  PubMed  CAS  Google Scholar 

  • Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV (2002) Behavioral naltrexone therapy: an integrated therapy for opiate dependence. J Subst Abuse Treat 23(4):351–360

    Article  PubMed  Google Scholar 

  • Sideroff SI, Charuvastra VS, Jarvik ME (1978) Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 5:415–423

    PubMed  CAS  Google Scholar 

  • Wang RIH, Wiesen RL, Lamid S, Roh BL (1974) Rating the presence and severity of opiate dependence. Clin Pharmacol Ther 16:653–658

    PubMed  CAS  Google Scholar 

  • Washton AM, Gold MS, Pottash AC (1984) Successful use of naltrexone in addicted physicians and business executives. Adv Alcohol Subst Abuse 4(2):89–96

    PubMed  CAS  Google Scholar 

  • Wesnes K, Warburton DM (1983) Effects of smoking on rapid information processing performance. Neuropsychobiology 9:223–229

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Michael R. Donovan, R.N.; Ronnie M. Shapiro, R.N.; Evaristo Akerele, M.D.; Adam Bisaga, M.D.; and Eric Rubin, M.D., Ph.D. for medical assistance; and Laura Andima, B.S., Kevin Walsh, B.S., and Christy Aberg, B.A. for technical assistance with this study. This research was supported by the National Institute on Drug Abuse (DA09236).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sandra D. Comer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sullivan, M.A., Vosburg, S.K. & Comer, S.D. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189, 37–46 (2006). https://doi.org/10.1007/s00213-006-0509-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-006-0509-x

Keywords

Navigation